Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Emerging Technologies in Vaccine Discovery and Development (J5)

joint with the meeting on Progress and Pathways Toward an Effective HIV Vaccine (J6)

Scientific Organizers: David Kaslow, Nicholas Jackson and Ann L. Lee


January 28—February 1, 2018

Fairmont Banff Springs, Banff, Alberta, Canada


Sponsored by Astellas Pharma Inc., Moderna Therapeutics and Pfizer Inc.
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation


IT’S NOT TOO LATE TO SUBMIT YOUR ABSTRACT. Abstracts received can no longer be considered for oral short talks. Abstracts for poster display opportunities will be accepted until 6 weeks before meeting start date midnight MST.
BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.

DEADLINES:
Global Health Travel Award Deadline: Aug 29, 2017 [details]
Scholarship Deadline: Oct 4, 2017 [details]
Discounted Abstract Deadline: Oct 4, 2017 [details]
Abstract Deadline: Nov 2, 2017 [details]
Discounted Registration Deadline: Dec 6, 2017 [details]

Click here to view Cancellation Policy

Submit an Abstract Register Yourself Deadlines and Fees

Rates and Deadlines listed below are for the 2018-J5 "Emerging Technologies in Vaccine Discovery and Development" conference only.

*All deadlines end at 11:59 PM US Mountain Standard Time

Deadline Date Cost
Discounted Abstract Deadline
More details
Before and On October 4, 2017 100.00 USD*
- 50.00 USD discount
Abstract Deadline
More details
After October 4, 2017 until December 17, 2017 100.00 USD*
* 50.00 USD of Abstract fee deducted from your registration fee when you register for this meeting
Scholarship
More details
October 4, 2017 n/a
Discounted NON-STUDENT Registration
More details
Before and On December 6, 2017 920.00 USD
(includes 200.00 discount)
Regular NON-STUDENT Registration
More details
After December 6, 2017 1120.00 USD
Discounted STUDENT Registration
More details
Before and On December 6, 2017 695.00 USD
(includes 200.00 discount)
Regular STUDENT Registration
More details
After December 6, 2017 895.00 USD

* Changes in payment type that result in a refund are subject to a processing fee.
* Currency exchange gains/losses are the responsibility of the registrant and the Keystone Symposia will accept no liability for money loss through bank charges, transfers or currency fluctuations.




Discounted Abstract Deadline: October 4, 2017


Abstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register

Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract early allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • accept your abstract online
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
(The Abstract Deadline: is November 2, 2017)

Global Health Travel Award Deadline: August 29, 2017


Global Health Travel Award Details: You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline and complete the other required steps (verify your contact information and submit a recommendation letter) to be considered for a travel award.


Click here to learn more about Global Health Travel Awards.

Scholarship Deadline: October 4, 2017


Scholarship Details: You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.

Click here to learn more about Scholarships.

Abstract Deadline: November 2, 2017


Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register

Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract by the Abstract Deadline allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.

(Discounted Abstract Deadline: is October 4, 2017)

Discounted Registration Deadline: December 6, 2017


Registration Fee: 920.00 USD* (includes 200.00 USD discount)
Student Registration Fee: 695.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

After the Discounted Registration Deadline:


Registration Fee: 1120.00 USD*
Student Registration Fee: 895.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

Registration spaces are limited and may fill prior to discounted registration deadline.

Please be advised that a few meeting participants have received calls and emails from a number of different housing services - "Exhibitors Housing Services", "Global Housing", etc. THESE COMPANIES ARE NOT AFFILIATED WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting is filling and seek to take your lodging reservation and obtain your credit card number. We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report to Keystone Symposia any calls or correspondence you might have received and book only through the lodging link on our website, an established travel agency, or directly with the hotel.
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, January 28 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 1 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 2 in order to fully experience the meeting.

SUNDAY, JANUARY 28

16:00—20:00
Arrival and Registration

Van Horne Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Van Horne Foyer

MONDAY, JANUARY 29

07:00—08:00
Breakfast

Mezzanine 2
08:00—09:00
Welcome and Keynote Address
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
Speaker to be Announced

08:00—09:00
Welcome and Keynote Address
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
Michel C. Nussenzweig, HHMI/Rockefeller University, USA
The HIV Vaccine Problem

09:00—11:15
New Tools in Antigen/Vaccine Discovery
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
Isabel Delany†, GSK Vaccines, Italy
Exploiting Pathogen Genomes for Vaccine Design

Coffee Break

Nicholas Jackson, Sanofi Pasteur, France
Novel Antigen Design and Functional Immune Assessments

Rafick-Pierre Sékaly, Case Western Reserve University, USA
Systems Biology and Vaccine Discovery

Short Talk(s) Chosen from Abstracts

09:00—11:15
Laying the Foundation for an HIV Vaccine
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
Dennis R. Burton, The Scripps Research Institute, USA
Neutralizing HIV Antibodies and Protection

Coffee Break

Barton F. Haynes, Duke University Medical Center, USA
Host Controls of Broadly Neutralizing Antibodies

M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Early Concepts to Advanced Stage HIV Clinical Studies

Short Talk(s) Chosen from Abstracts

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Mezzanine 2
13:00—22:00
Poster Viewing

Mezzanine 2
14:30—16:30
Workshop 1: Assessing Immunogenicity in Animal to Predict Outcomes in Humans

Van Horne A/B
Short Talks Chosen from Abstracts

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Structural Immunology Guiding Vaccine Development (Joint)
Registered attendees can view abstracts starting on 12/28/2017

Pamela J. Bjorkman, California Institute of Technology, USA
Structural Studies of Antibody and Receptor Binding to HIV-1 Env

Jason S. McLellan, University of Texas at Austin, USA
Structure-based Vaccine Design for Class I Viral Fusion Glycoproteins

Andrew B. Ward, The Scripps Research Institute, USA
Using Structures to Guide Env Immunogen Design and Redesign

Short Talk Chosen from Abstracts

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
19:30—22:00
Poster Session 1

Mezzanine 2

TUESDAY, JANUARY 30

07:00—08:00
Breakfast

Mezzanine 2
08:00—11:00
New Platforms for Active Immunization
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
Klaus Früh, Oregon Health & Science University, USA
CMV-Vectored Vaccines for Eliciting Cellular Immunity

Speaker to be Announced

Coffee Break

Richard Malley, Boston Children's Hospital, USA
Generating Broad B- and T-Cell Immunity via the Multiple Antigen Presenting System (MAPS)

Speaker to be Announced

Short Talk(s) Chosen from Abstracts

08:00—11:00
Germinal Centers, B/T Cell Interactions
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
Shane Crotty, La Jolla Institute for Allergy and Immunology, USA
Assessing the Engines of Affinity Maturation: Germinal Centers and Tfh Cells

Gabriel D. Victora, Rockefeller University, USA
Antibody Affinity Maturation in Germinal Centers

Coffee Break

Facundo D. Batista, Ragon Institute of MGH, MIT and Harvard, USA
B Cell Activation Induces a Switch from Canonical to Non-Canonical Autophagy that Shapes B Cell Fate

Garnett H. Kelsoe, Duke University and Medical Center, USA
Mechanisms of Selection in Germinal Centers

Short Talk(s) Chosen from Abstracts

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Mezzanine 2
13:00—22:00
Poster Viewing

Mezzanine 2
14:30—16:30
Workshop 2: Epidemic Preparedness Innovation

Van Horne A/B
David C. Kaslow, PATH, USA
Just-in-Time and Just-in-Case Vaccines Approaches to Epidemic Preparedness

Short Talks Chosen from Abstracts

14:30—16:30
Workshop 1: Lessons Learned from Efficacy Studies

Van Horne C
Short Talks Chosen from Abstracts

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
New Platforms for Passive Immunization
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
JoAnn A. Suzich, MedImmune, USA
Multi-Mechanistic Monoclonal Antibody-Based Approaches for Passive Immunoprophylaxis

Alejandro Balazs, Massachusetts General Hospital, USA
Development of Vectored ImmunoTherapy Reveals Escapability as a Key Feature of Broadly Neutralizing Antibodies

Speaker to be Announced

Short Talk Chosen from Abstracts

17:00—19:00
Model Systems for HIV Vaccine Development
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
George M. Shaw, University of Pennsylvania, USA
Recapitulation of HIV-1 Envelope-Antibody Coevolution in Rhesus Macaques Leading to Strain-Specific and Broadly Neutralizing Antibodies

Pia Dosenovic, Rockefeller University, USA
Activation of HIV-1-Specific B Cell Precursors in the Presence of a Polyclonal Immune System

Andres Finzi, CRCHUM / Université de Montréal, Canada
Impact of Env Conformation on ADCC Responses

Short Talk Chosen from Abstracts

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
19:30—22:00
Poster Session 2

Mezzanine 2

WEDNESDAY, JANUARY 31

07:00—08:00
Breakfast

Mezzanine 2
08:00—11:00
New Tools in Interrogating Human Immune Responses (Joint)
Registered attendees can view abstracts starting on 12/28/2017

Bette Tina Marie Korber, Los Alamos National Laboratory, USA
Computational Tools for Antigen Design

William H. Robinson, Stanford University School of Medicine, USA
Sequencing the Functional Antibody Repertoire

Coffee Break

Louis J. Picker, Oregon Health & Science University, USA
Immune Programming with CMV Vectors

Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA
Characterizing the Cellular and Humoral Response of Human Volunteers Challenged with Live Attenuated Viruses

Short Talk(s) Chosen from Abstracts

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Mezzanine 2
13:00—22:00
Poster Viewing

Mezzanine 2
14:30—16:30
Workshop 2: Young Investigators, Vaccine Evaluation

Van Horne C
Short Talks Chosen from Abstracts

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
New Approaches in Vaccine Clinical Trial Design
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
Thomas Evans, TomegaVax, USA
Mathematical Modelling Human Immune Responses to Design more Efficient Vaccine Clinical Development

Ashley J. Birkett, PATH Malaria Vaccine Initiative, USA
New Approaches in Vaccine Clinical Trial Design: Maximizing Malaria Vaccine Efficacy and Informing Next-Generation Efforts

M. Elizabeth Halloran, University of Washington, USA
Novel Trial Designs for Measuring Direct and Indirect Effects of Vaccination

Short Talk Chosen from Abstracts

17:00—19:00
New Insights into HIV Transmission and Infection
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
Beatrice H. Hahn, University of Pennsylvania, USA
Determinants of HIV-1 Transmission Fitness

Stuart J. Neil, King's College London, UK
Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction

Lynn Morris, National Institute for Communicable Diseases, South Africa
Vaccine-Induced Protection Against Clade C HIV-1 Variants Prospects for an HIV-1 Vaccine

Short Talk Chosen from Abstracts

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
19:30—22:00
Poster Session 3

Mezzanine 2

THURSDAY, FEBRUARY 1

07:00—08:00
Breakfast

Mezzanine 2
08:00—11:00
New Tools in Vaccine Manufacturing and Product Analytics
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
Sangeetha L. Sagar, Sanofi Pasteur, USA
Advances and Challenges in Vaccine Development and Manufacture

Sabine M.G. van der Sanden†, Academic Medical Center, University of Amsterdam, Netherlands
Engineering Enhanced Vaccine Cell Lines with CRISPR/Cas9-Mediated Knockouts

Coffee Break

James N. Thomas, Just Biotherapeutics, USA
Low-Cost Manufacturing and more Stable Immunobiologics for Use in Low and Middle-Income Countries

Ann L. Lee, Genentech, Inc., USA
Smart Bioprocessing Strategies for Immunobiologics

Short Talk(s) Chosen from Abstracts

08:00—11:00
Induction of Broad Neutralizing Antibodies by Vaccination
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
Leonidas Stamatatos, Fred Hutchinson Cancer Research Center, USA
Targeted Expansion and Maturation of bNAb B Cell Precursors

John R. Mascola, NIAID, National Institutes of Health, USA
Strategies to Elicit HIV-1 Fusion Peptide directed Neutralizing Antibodies.

Coffee Break

William Schief, IAVI and The Scripps Research Institute, USA
Toward Elicitation of Broadly Neutralizing Antibodies by Germline-Targeted Priming and Structure-Guided Boosting

Rogier W. Sanders, Weill Medical College of Cornell University, USA
Native-like HIV-1 Envelope Trimers as a Platform to Activate Germline Precursors of Broadly Neutralizing Antibodies

Short Talk(s) Chosen from Abstracts

11:00—17:00
On Own for Lunch

14:30—16:30
Workshop 3: How Best to Meet the Increasing Challenges Faced in Vaccine Development

Van Horne A/B
Short Talks Chosen from Abstracts

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—18:45
New Tools in Vaccine Formulation and Delivery
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
Nathalie Garçon, Bioaster, France
Adjuvants: From 1920 to 2018 and Beyond

Rhea N. Coler, Infectious Disease Research Institute, USA
Enhancing Immunogenicity and Protective Efficacy through Novel Adjuvants and Formulations

Mark C. Poznansky, Massachusetts General Hospital, USA
Accelerated Development of a T Cell-Based Vaccine for Q Fever

17:00—18:45
Antibodies as Immunoprophylaxis and Treatment
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
Marina F. Caskey, Rockefeller University, USA
Effects of Potent Broad Neutralizing Antibody Combinations in Humans

Julie Ledgerwood, NIAID, National Institutes of Health, USA
Passive Immunization of HIV-1 Neutralizing Monoclonal Antibodies in Clinical Trials

David Ho, Aaron Diamond AIDS Research Center, USA
Engineering HIV-Neutralizing Bispecific Antibodies

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 12/28/2017

Van Horne A/B
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 12/28/2017

Van Horne C
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Mezzanine 2

FRIDAY, FEBRUARY 2

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Astellas Pharma Inc. Bill & Melinda Gates Foundation
Moderna Therapeutics Pfizer Inc.

We gratefully acknowledge additional support for this conference from:

Avanti Polar Lipids, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676